Ppar Articles

Single, dual and pan-PPAR agonists are under development for the pharmacological treatment of NASH, ? read more from our articles.

Hepatic inflammatory responses in liver fibrosis

Authors: Hammerich L, Tacke F
Published in Nature reviews gastroenterology & hepatology
Recent technological advancements have provided unprecedented insights into the inflammatory mechanisms underlying liver fibrosis, leading to the identification of promising novel targets for anti-inflammatory and antifibrotic therapies.
Read MoreHepatic inflammatory responses in liver fibrosis

Exploring the Promise of Pan-PPAR Agonism

Authors: Staels B, Butruille L, and Francque S
Published in Journal of Hepatology (November 2023)
Peroxisome proliferated-activated receptors (PPARs), including α, β/δ and γ isotypes, are a nuclear receptor family of lipid sensors activated by natural fatty acid derivatives and pharmacological agonists.
Read MoreExploring the Promise of Pan-PPAR Agonism

Exploring Emerging Anti-Inflammatory and -Fibrotic Therapeutic Targets for NASH

Authors: Tacke F, Puengel T, Loomba R et al.
Published in Journal of Hepatology (August 2023)
Non-alcoholic fatty liver disease (NAFLD) can be categorised into two disease sub-classifications: non-alcoholic fatty liver (NAFL), its non-progressive subtype, and non-alcoholic steatohepatitis (NASH), its progressive form.
Read MoreExploring Emerging Anti-Inflammatory and -Fibrotic Therapeutic Targets for NASH

PPAR-modulating Drugs For Nash: Lessons Learned From Pre-clinical And Clinical Data

Authors: Staels B, Butruille L, Francque S
Published in Journal of Hepatology (July 2023)
Non-alcoholic steatohepatitis (NASH) is characterised by complex interactions between intricate intra- and extra-hepatic drivers, encompassing numerous metabolic, inflammatory, vascular, and fibrogenic pathways. Categories: PPAR Articles, NASH Biomarker, Pathophysiology Articles, Management Articles
Read MorePPAR-modulating Drugs For Nash: Lessons Learned From Pre-clinical And Clinical Data

A brief introduction to the most promising pharmacological agents for NASH

Authors: Ratziu V and Tacke F
Published in Journal of Hepatology (July 2023)
The last decade has seen an unprecedented amount of data in the way of therapeutic research for non-alcoholic steatohepatitis (NASH), the progressive form of non-alcoholic fatty liver disease (NAFLD).
Read MoreA brief introduction to the most promising pharmacological agents for NASH

Anti-inflammatory and Antifibrotic Targets for the Treatment of NASH: a Review

Authors: Tacke F, Puengel T, Loomba R et al
Published in J Hepatol (April 2023)
Generally, NASH and fibrosis correlate with the development of cirrhosis and other negative clinical outcomes. Treatments often aim to target inflammation, fibrosis, cell injury or metabolic dysregulation.
Read MoreAnti-inflammatory and Antifibrotic Targets for the Treatment of NASH: a Review

The PPARα-FABP1 Axis: A New Target for NASH Therapies?

Authors: Yan T, Luo Y, Yan N et al.
Published in Hepatology 2023
Although it is known that non-alcoholic steatohepatitis (NASH) increases the risk of end-stage liver diseases such as cirrhosis and hepatocellular carcinoma, no pharmacologic therapy has yet been approved to treat it.
Read MoreThe PPARα-FABP1 Axis: A New Target for NASH Therapies?

Emerging drugs targeting specific points in NASH pathogenesis

Authors: Stojsavljevic-Shapeski S, Duvnjak M, Virovic-Jukic L,
et al.
Published in J Clin Transl Hepatol 2021
Extensive research and revelation in the field of pathogenesis of NASH has offered new possibilities of treatment and emerging new drugs that are being tested currently in numerous preclinical and clinical trials. These drugs target almost all steps in the pathogenesis of NASH...
Read MoreEmerging drugs targeting specific points in NASH pathogenesis

Pharmacotherapy in NAFLD/NASH

Authors: Attia SL, Softic S, Mouzaki M.
Published in Clin Transl Sci 2021
This review by SL Attia et al. (University of Kentucky College of Medicine, USA) summarises emerging pharmacotherapies for the treatment of adult and paediatric NAFLD. Investigated pharmacotherapies include lanifibranor (IVA337), an indole sulfonamide PPAR agonist that activates....
Read MorePharmacotherapy in NAFLD/NASH

PPARs as candidates for the treatment of NAFLD

Authors: Fougerat A, Montagner A, Loiseau N, et al
Published in Cells 202
The prevalence of NAFLD is dramatically increasing in developed countries, but no approved therapy is available. Most of the current pharmacological strategies target comorbidities, such as manifestations of metabolic syndrome. In addition, none of used medications improve fibrosis, which is the strongest indicator of mortality in NAFLD...
Read MorePPARs as candidates for the treatment of NAFLD

Fibrosis in NASH: targeted therapies

Authors: Huisman TM, Dieterich DT, Friedman SL
Published in J Exp Pharmacol 2021
Progress in uncovering pathogenic determinants of fibrosis in NASH include metabolic dysregulation in hepatocytes that induce inflammation and cytokine secretion leading to cell injury and apoptosis, among others.This review by T. M. Huisman et al. (Division of Liver Diseases, Icahn School of Medicine at Mount Sinai...
Read MoreFibrosis in NASH: targeted therapies

Management of NAFLD: a review

Authors: Petroni ML, Brodosi L, Bugianesi E, et al.
Published in BMJ 2021
As explained in the review by M. L. Petroni et al. (“Alma Mater” University, Bologna, Italy), several drugs are under investigation according to the agreed targets of reduced NASH activity without worsening of fibrosis or improving fibrosis without worsening of NASH. Anti-inflammatory, anti-fibrotic agents and metabolism modulators...
Read MoreManagement of NAFLD: a review

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES